Asset Dedication’s Alnylam Pharmaceuticals ALNY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$1.23K Sell
5
-1
-17% -$254 ﹤0.01% 1057
2026
Q2
$1.81K Buy
6
+1
+20% +$302 ﹤0.01% 1049
2026
Q1
$1.66K Hold
5
– – ﹤0.01% 982
2025
Q4
$1.99K Hold
5
– – ﹤0.01% 1008
2025
Q3
$2.28K Buy
+5
New +$2.04K ﹤0.01% 1008
2023
Q1
– Sell
-1
Closed – – 946
2022
Q4
$0 Buy
+1
New +$213 ﹤0.01% 989
2021
Q4
– Sell
-16
Closed -$3K – 922
2021
Q3
$3K Buy
+16
New +$3K ﹤0.01% 853
2018
Q2
– Sell
-75
Closed -$9K – 612
2018
Q1
$9K Buy
+75
New +$9.7K ﹤0.01% 382

Other funds holding ALNY

Asset Dedication's ALNY Position: Q3 2026 in Review

Asset Dedication reduced its Alnylam Pharmaceuticals (ALNY) stake by 17% in Q3 2026, selling an estimated $254 and leaving 5 shares worth $1.23K. The position accounts for ﹤0.01% of the portfolio, ranked #1057.

Asset Dedication first reported a position in ALNY in Q1 2018 and has held it in 8 quarters since. The position peaked at $9K in Q1 2018. 591 funds tracked by Wall St. Rank hold ALNY as of Q3 2026.

  • Asset Dedication held 5 shares of Alnylam Pharmaceuticals worth $1.23K as of Q3 2026.
  • Asset Dedication sold 1 Alnylam Pharmaceuticals share in Q3 2026, an estimated $254.
  • Alnylam Pharmaceuticals made up ﹤0.01% of Asset Dedication's portfolio in Q3 2026, its #1057 holding.
  • Asset Dedication first reported a position in Alnylam Pharmaceuticals in Q1 2018 and has held it in 8 quarters since.
  • Asset Dedication's Alnylam Pharmaceuticals position peaked at $9K in Q1 2018.
  • 591 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q3 2026.

Based on Asset Dedication's 13F filing for Q3 2026, filed 3 Nov 2026.